Evolving Role of B7-H3–Directed ADCs in the Extensive-Stage Small-Cell Lung Cancer Treatment Landscape

In this podcast episode, Charles Rudin, MD, PhD, and Mark A. Socinski, MD, discuss current gaps and clinical needs for patients with relapsed ES-SCLC, and the evolving role of B7-H3–directed antibody–drug conjugates in the management of patients with ES-SCLC, including:Clinical needs for relapsed ES-SCLCScientific rationale for targeting B7-H3 and other tumor-associated antigens in SCLCADCs, T-cell engagers, chemotherapy-based approaches, maintenance strategies, and ongoing clinical trials for ES-SCLCRecent efficacy and safety data for B7-H3–directed ADCs in ES-SCLC, including I-DXdPersonalization of care of patients with SCLC, including patient-specific factors influencing treatmentCase discussion of a patient with ES-SCLC requiring optimal next best treatmentImportance of enrolling patients in ongoing trials of investigational agents for patients with ES-SCLCPresenters:Charles Rudin, MD, PhDCancer Center DirectorMemorial Sloan Kettering Cancer CenterNew York, New YorkMark A. Socinski, MDExecutive Medical DirectorAdventHealth Cancer InstituteOrlando, FloridaLink to full program:https://bit.ly/3UBEeYz Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.